Comparison of the Efficiency and Safety of Photodynamic Therapy Combined Intravitreal Bevacizumab and Intravitreal Triamcinolone Treatments in Age-Related Macular Degeneration

Main Article Content

Meltem Erden
Feyza Önder
Bedriye Nur Sur Ayrancıoğlu

Abstract

Objective: This study aims to retrospectively examine the mid and long-term results of the photodynamic therapy (PDT) +IVTA group and the PDT +IVB applied Group in the treatment of choroid neovascularization (CNV) due to age-related macular degeneration (AMD) and to compare the results with the results of multicenter clinical studies.


Materials and Methods: 64 eyes of 64 patients admitted to Haseki Training and Research Hospital, Department of Ophthalmology, Retina unit between June 2003 and March 2009, diagnosed with CNV secondary to age-related macular degeneration and treated, were included in the study. Thirty-five eyes with PDT +IVTA were classified as Group I, and 29 with PDT +IVTA were classified as Group II. Visual acuities of the cases were evaluated with ETDR and Snellen charts and converted to their equivalents on the Logarithm of Minimal Angle of Resolution (logMAR) scale. All patients underwent an ophthalmological examination before and after the treatment; fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) were performed to see if there was any recurrence in the patients. Patients who were found to have relapsed were re-treated.


Results: There were 26 (40.6%) female cases and 38 (59.4%) male cases. The ages ranged from 55 to 88, with a mean age of 73.85±7.26. The follow-up period of the patients ranged from 5 months to 69 months; the mean was 17.65±13.48 months. When evaluated according to FFA images, 40 (62.5%) were occult, 12 (18.8%) were minimal-classical, and 12 (18.8%) were dominant-classical. After treatment, visual acuity decreased in 20% of the PDT +IVTA group and increased or remained the same in 80%. In the PDT +IVB group, blurred vision decreased by 27.6% and increased or remained the same by 72.4%. There was no statistically significant difference between the groups regarding the change in visual acuity after treatment compared to before treatment (p>0.05). In OCT, the decrease in the mean central foveal thickness (CFT) after treatment compared to the mean CFT before treatment in Group I was statistically significant (p<0.05). In Group II - the decrease in the mean CFT after treatment compared to the mean CFT before treatment was statistically significant (p<0.01). In Group I, there was no statistically significant change in the mean lesion diameter after treatment compared to the mean lesion diameter before treatment (p>0.05). However, the decrease in Group II was statistically significant (p<0.01). While the increase in CFT (central foveal thickness) and lesion diameter was more pronounced in the PDT+IVTA group post-treatment compared to the pre-treatment group, no significant difference was observed in visual acuity change within the PDT+IVTA group.


Conclusion: In the treatment of choroidal neovascularization secondary to age-related macular degeneration, the combination of Triamcinolone or Bevacizumab with photodynamic therapy has proven to be both effective and safe. This approach helps preserve the current vision and even enhance visual outcomes. Combination therapy reduces the frequency and number of monotherapies used to achieve visual success.

Downloads

Download data is not yet available.

Article Details

How to Cite
Erden, M., Önder, F., & Sur Ayrancıoğlu, B. N. . (2024). Comparison of the Efficiency and Safety of Photodynamic Therapy Combined Intravitreal Bevacizumab and Intravitreal Triamcinolone Treatments in Age-Related Macular Degeneration. Medical Science and Discovery, 11(1), 1–7. https://doi.org/10.36472/msd.v11i1.1002
Section
Research Article
Received 2023-07-21
Accepted 2023-12-27
Published 2024-01-01

References

De Jong PT. Age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1474-85. DOI: https://doi.org/10.1056/NEJMra062326

Chew EY, Clemons TE, Agrón E, Sperduto RD, SanGiovanni JP, Davis MD, et al. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA ophthalmology. 2014;132(3):272-7. DOI: https://doi.org/10.1001/jamaophthalmol.2013.6636

Group ToA-RMDwPTS. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. Archives of Ophthalmology. 2001;119(2):198-207.

Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology. 2003;110(4):667-73. DOI: https://doi.org/10.1016/S0161-6420(02)01998-X

Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Archives of Ophthalmology (Chicago, Ill: 1960). 2003;121(9):1253-68. DOI: https://doi.org/10.1001/archopht.121.9.1253

Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27(2):133-40. DOI: https://doi.org/10.1097/IAE.0b013e3180323de7

Koh A, Lee WK, Chen L-J, Chen S-J, Hashad Y, Kim H, et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453-64. DOI: https://doi.org/10.1097/IAE.0b013e31824f91e8

Kaiser PK, Committee RoVATW. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009;116(4):747-55. e1. DOI: https://doi.org/10.1016/j.ophtha.2008.12.057

Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina (Philadelphia, Pa). 2004;24(1):1-12. DOI: https://doi.org/10.1097/00006982-200402000-00001

Cruess AF, Zlateva G, Pleil AM, Wirostko B. Photodynamic therapy with verteporfin in age‐related macular degeneration: a systematic review of efficacy, safety, treatment modifications and pharmacoeconomic properties. Acta ophthalmologica. 2009;87(2):118-32. DOI: https://doi.org/10.1111/j.1755-3768.2008.01218.x

Mittra RA, Singerman LJ. Recent advances in the management of age-related macular degeneration. Optometry and vision science. 2002;79(4):218-24. DOI: https://doi.org/10.1097/00006324-200204000-00008

Chan W, Lai T, Wong A, Tong J, Liu D, Lam D. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. British journal of ophthalmology. 2006;90(3):337-41. DOI: https://doi.org/10.1136/bjo.2005.081299

Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Advanced drug delivery reviews. 2005;57(14):1994-2009. DOI: https://doi.org/10.1016/j.addr.2005.09.003

Finger RP, Wickremasinghe SS, Baird PN, Guymer RH. Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Survey of ophthalmology. 2014;59(1):1-18. DOI: https://doi.org/10.1016/j.survophthal.2013.03.009

Abedi F, Wickremasinghe S, Islam AF, Inglis KM, Guymer RH. Anti-VEGF treatment in neovascular age–related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34(8):1531-8. DOI: https://doi.org/10.1097/IAE.0000000000000134

Gemenetzi M, Patel PJ. A systematic review of the treat and extend treatment regimen with anti-VEGF agents for neovascular age-related macular degeneration. Ophthalmology and therapy. 2017;6:79-92. DOI: https://doi.org/10.1007/s40123-017-0087-5

Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, et al. Real-world vision in age-related macular degeneration patients treated with single anti–VEGF drug type for 1 year in the IRIS registry. Ophthalmology. 2018;125(4):522-8. DOI: https://doi.org/10.1016/j.ophtha.2017.10.010

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine. 2006;355(14):1419-31. DOI: https://doi.org/10.1056/NEJMoa054481

Campa C, P Harding S. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Current drug targets. 2011;12(2):173-81. DOI: https://doi.org/10.2174/138945011794182674

Adrean SD, Chaili S, Ramkumar H, Pirouz A, Grant S. Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti–VEGF injections using a treat-extend-stop protocol. Ophthalmology. 2018;125(7):1047-53. DOI: https://doi.org/10.1016/j.ophtha.2018.01.012

Papadopoulos Z. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration. European journal of ophthalmology. 2019;29(4):368-78. DOI: https://doi.org/10.1177/1120672119832432

W Stewart M. Aflibercept (VEGF-TRAP): the next anti-VEGF drug. Inflammation & Allergy-Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy)(Discontinued). 2011;10(6):497-508. DOI: https://doi.org/10.2174/187152811798104872

Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. American journal of ophthalmology. 2009;148(1):43-58. e1. DOI: https://doi.org/10.1016/j.ajo.2009.01.024

Dhalla MS, Shah GK, Blinder KJ, EDWIN H RYAN J, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006;26(9):988-93. DOI: https://doi.org/10.1097/01.iae.0000247164.70376.91

Loukianou E, Loukianou G. Intravitreal aflibercept in recalcitrant radiation maculopathy due to external beam radiotherapy for nasopharyngeal cancer: a first case report. Case reports in ophthalmology. 2017;8(1):87-90. DOI: https://doi.org/10.1159/000456535

Murray TG, Latiff A, Villegas VM, Gold AS. Aflibercept for radiation maculopathy study: a prospective, randomized clinical study. Ophthalmology Retina. 2019;3(7):561-6. DOI: https://doi.org/10.1016/j.oret.2019.02.009

Wong RL, Lai TY. Polypoidal choroidal vasculopathy: an update on therapeutic approaches. Journal of ophthalmic & vision research. 2013;8(4):359.